Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc ...

Canaccord analyst Kingsley Crane raised the firm’s price target on CrowdStrike (CRWD) to $420 from $370 and keeps a Buy rating on the shares.

Canaccord raised the firm’s price target on Okta (OKTA) to $100 from $94 and keeps a Hold rating on the shares. The firm said they reported ...

TTEC (NASDAQ:TTEC – Free Report) had its target price reduced by Canaccord Genuity Group from $4.50 to $3.50 in a research ...

Clover Health Investments (NASDAQ:CLOV – Free Report) had its target price raised by Canaccord Genuity Group from $4.20 to $4.50 in a research report report published on Monday morning,Benzinga ...

Fintel reports that on February 28, 2025, Canaccord Genuity downgraded their outlook for ICF International (NasdaqGS:ICFI) ...

Analysts at Canaccord Genuity reiterated their 135.0p target price on airside solutions developer Aurrigo International on ...

Canaccord Genuity Sustainability Virtual Summit February 26, 2025 2:20 PM ETCompany ParticipantsRyan Corbett - Chief ...

Fintel reports that on February 19, 2025, Canaccord Genuity initiated coverage of Candel Therapeutics (NasdaqGM:CADL) with a ...

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today ...

The sale of Brooks Macdonald Asset Management (International) to Canaccord Genuity Wealth (International) has completed for ...

Canaccord Genuity raised its price target on Snowflake (NYSE:SNOW) by $30 to $220, as company is set to report fourth-quarter earnings on Wednesday. Stabilizing growth and AI-driven expansion are key ...